enGene Therapeutics Reports Positive Phase 2 LEGEND Trial Data for Detalimogene
enGene Therapeutics (ENGN) has announced updated results from Cohort 1 of its Phase 2 LEGEND clinical trial. The study evaluates the efficacy and safety of detalimogene in patients suffering from high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Building on these positive outcomes, the company intends to use data from a total of 125 patients to support its upcoming Biologics License Application (BLA) submission. This development marks a significant regulatory milestone for enGene's oncology pipeline.
Tickers: $ENGN
Topics: bladder cancer clinical data update detalimogene Phase 2 trial